Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa | Zendy

Gail Matthews | Zendy; Prince Manzini | Zendy; Zonghui Hu | Zendy; Paul Khabo | Zendy; Patrick Maja | Zendy; Gugu Matchaba | Zendy; Phumele Sangweni | Zendy; Julie A. Metcalf | Zendy; Nicholaas Pool | Zendy; Susan Orsega | Zendy; Sean Emery | Zendy

Open Access

Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa

Author(s) -

Gail Matthews,

Prince Manzini,

Zonghui Hu,

Paul Khabo,

Patrick Maja,

Gugu Matchaba,

Phumele Sangweni,

Julie A. Metcalf,

Nicholaas Pool,

Susan Orsega,

Sean Emery

Publication year - 2011

Publication title -

aids

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.195

H-Index - 216

eISSN - 1473-5571

pISSN - 0269-9370

DOI - 10.1097/qad.0b013e328349bbf3

Subject(s) - lamivudine , coinfection , medicine , stavudine , hepatitis b virus , hepatitis b , virology , immunology , didanosine , zidovudine , gastroenterology , virus , viral disease

To examine HIV and hepatitis B virus (HBV)-related outcomes in HIV/HBV-coinfected participants in the PHIDISA II study by use of HBV-active vs. non-HBV-active antiretroviral therapy (ART).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research